Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Prostate Cancer Drug Market Analysis US, Canada & Australia to 2022

221 views

Published on

Buy the report "US, Canada & Australia Prostate Cancer Drug Forecast and Market Analysis to 2022" at US $4995 for a Single User PDF License from RnR Market Research Reports Library. PharmaPoint: Prostate Cancer – US, Canada & Australia Drug Forecast and Market Analysis to 2022

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Prostate Cancer Drug Market Analysis US, Canada & Australia to 2022

  1. 1. RnRMarketResearch Offers “US, Canada & Australia Prostate Cancer Drug Forecast andMarket Analysis to 2022” Report at US$ 4995 (Single User License). The report got publishedin Dec 2012.GlobalData has released its new Country report, “PharmaPoint: Prostate Cancer – US, Canada & AustraliaDrug Forecast and Market Analysis to 2022″. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’Xtandi (enzalutamide) will drive strong market growth over the next decade. These safe and orallyadministered treatments will provide safety and convenience benefits over the current standard of care,chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12,2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of anew treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy andbeyond. For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists andfirst-generation antiandrogens remains the standard of care for suppressing testosterone levels andtemporarily controlling the disease.Prostate Cancer United States Drug Market Analysis to 2022US prescribers widely use routine PSA screening to diagnose prostate cancer, as well as a DRE. GlobalData’sprimary research shows that the majority of patients treated by urologists and medical oncologists in the US in2011 were diagnosed or monitored using PSA screening. The diagnosis is confirmed and the cancer is stagedfollowing a TRUS-guided multiple-core needle biopsy, and any metastases are diagnosed using a bone scanor Computed Tomography (CT) scan (NCCN, 2012). Most prescribers surveyed intend to decrease their use ofroutine PSA screening to diagnose prostate cancer in asymptomatic patients in response to the recentUSPSTF recommendation against it (see Section 5.2.2). While GlobalData predicts that the use of routine PSAscreening will slightly decrease, we still believe that it will be the primary tool used in the diagnosis of prostatecancer over the forecast period, as there are currently no better, cost-effective options available.Request a Sample Copy of US @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=77506Prostate Cancer Canada Drug Market Analysis to 2022In Canada, prostate cancer is diagnosed following an abnormal DRE, elevated PSA levels detected duringroutine screening, or a patients’ presentation with symptoms that leads to either of these tests. A suspecteddiagnosis of prostate cancer is confirmed by TRUS-guided multiple core needle biopsies, and bone metastasesare detected using a CT scan or bone scan. The uptake of routine PSA screening has been high in Canada,but some Canadian physicians surveyed by GlobalData reported that they plan to decrease their use of routinescreening in response to the recent USPSTF recommendation against it (Baade et al., 2009).Request a Sample Copy of Canada @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=77514Prostate Cancer Australia Drug Market Analysis to 2022In Australia, prostate cancer is diagnosed following a patient’s presentation with symptoms, elevated PSAlevels as a result of routine screening, or an abnormal DRE. The diagnosis is confirmed after multiple coreneedle biopsies or TRUS, and bone metastases are detected by CT or bone scan. Routine PSA screening ismore commonly used in Australia compared with the 5EU, but less frequently than in the US (Baade et al.,2009).
  2. 2. Request a Sample Copy of Australia @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=77513Scope- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelinesas well as an overview on the competitive landscape.- Detailed information on the key drugs in the US including product description, safety and efficacy profiles aswell as a SWOT analysis.- Sales forecast for the top drugs in the US from 2012 to 2022.- Analysis of the impact of key events as well the drivers and restraints affecting the US Prostate cancermarket.Reasons to buy- Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising salespotential- Make more informed business decisions from insightful and in-depth analysis of Prostate cancer drugperformance in the US- Obtain sales forecast from 2012-2022 in The USTable of Content1 Table of Contents1 Table of Contents 41.1 List of Tables 71.2 List of Figures 82 Introduction 92.1 Catalyst 92.2 Related Reports 92.3 Upcoming Related Reports 113 Disease Overview 123.1 Etiology and Pathophysiology 123.1.1 Etiology 123.1.2 Pathophysiology 123.1.3 Prognosis 133.1.4 Quality of Life 143.2 Symptoms 144 Disease Management 154.1 Diagnosis and Referral Overview 154.2 Treatment Overview 174.2.1 Conservative Management Strategies 214.2.2 Localized Treatments 224.2.3 Hormone Therapy 234.2.4 Drug Therapies 254.3 US 264.3.1 Diagnosis 264.3.2 Clinical Practice 265 Competitive Assessment 28
  3. 3. 5.1 Overview 285.2 Strategic Competitor Assessment 295.3 Product Profiles - Major Brands, Hormone Therapies 325.3.1 Zoladex (goserelin acetate) 325.3.2 Lupron Depot (leuprolide acetate) 355.3.3 Eligard (leuprolide acetate) 395.3.4 Trelstar (triptorelin acetate) 425.3.5 Firmagon (degarelix) 455.3.6 Casodex (bicalutamide) 485.4 Product Profiles - Major Brands, Chemotherapies 525.4.1 Taxotere (docetaxel) 525.4.2 Jevtana (cabazitaxel) 555.5 Product Profiles - Major Brands, Therapeutic Vaccines 595.5.1 Provenge (sipuleucil-T) 595.6 Product Profiles - Major Brands, Targeted Therapies 645.6.1 Zytiga (abiraterone acetate) 645.6.2 Xtandi (enzalutamide) 685.7 Product Profiles - Major Brands, Bone Therapies 725.7.1 Xgeva (denosumab) 725.7.2 Zometa (zoledronic acid) 755.8 Other Marketed Hormone and Drug Therapies 786 Opportunity and Unmet Need 796.1 Overview 796.2 Efficacy at Prolonging Overall Survival 806.3 Safety 806.4 Mitigation of Symptoms 816.5 Cost 816.6 Convenient Routes of Administration 816.7 Accurate Diagnostic Tests and Surveillance Tools 826.8 Unmet Needs Gap Analysis 826.9 Opportunity: Targeting Early-Stage, Hormone-Sensitive Prostate Cancer 847 Pipeline Assessment 857.1 Overview 857.2 Promising Drugs in Clinical Development 867.2.1 Cabozantinib 887.2.2 Custirsen Sodium 927.2.3 Sprycel (dasatinib) 977.2.4 Yervoy (ipilimumab) 1017.2.5 Orteronel 1057.2.6 Alpharadin (radium-223 chloride) 1097.2.7 Tasquinimod 1147.2.8 ProstVac (Vaccinia-PSA-TRICOM/Fowlpox-PSA-TRICOM) 1188 Market Outlook 1228.1 United States 1228.1.1 Forecast 1228.1.2 Key Events 1258.1.3 Drivers and Barriers 1259 Appendix 1289.1 Bibliography 1289.2 Abbreviations 1419.3 Methodology 1439.4 Forecasting Methodology 143
  4. 4. 9.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment 1439.4.2 Percent Drug-treated Patients 1449.4.3 Percent Hormone Therapy-Treated Patients 1449.4.4 Drugs Included in Each Therapeutic Class 1449.4.5 Launch, Patent and Market Exclusivity Expiry Dates 1459.4.6 General Pricing Assumptions 1469.4.7 Individual Drug Assumptions 1489.4.8 Generic Erosion 1579.4.9 Pricing of Pipeline Agents 1579.5 Physicians and Specialists Included in This Study 1599.6 Survey of Prescribing Physicians 1599.7 About the Authors 1609.7.1 Authors 1609.7.2 Global Head of Healthcare 1619.8 About GlobalData 1629.9 Contact Us 1629.10 Disclaimer 1621.1 List of TablesTable 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets 13Table 2: Global Variations in Recommendations on Routine PSA Screening 15Table 3: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 2012 18Table 4: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets, 2012 20Table 5: Leading Treatments for Prostate Cancer, 2012 31Table 6: Product Profile - Zoladex 33Table 7: Zoladex SWOT Analysis, 2012 35Table 8: Product Profile - Lupron Depot 36Table 9: Lupron Depot SWOT Analysis, 2012 38Table 10: Product Profile - Eligard 40Table 11: Eligard SWOT Analysis, 2012 42Table 12: Product Profile - Trelstar 43Table 13: Trelstar SWOT Analysis, 2012 45Table 14: Product Profile - Firmagon 46Table 15: Firmagon SWOT Analysis, 2012 48Table 16: Product Profile - Casodex 49Table 17: Casodex SWOT Analysis, 2012 51Table 18: Product Profile - Taxotere 53Table 19: Taxotere SWOT Analysis, 2012 55Table 20: Product Profile - Jevtana 56Table 21: Jevtana SWOT Analysis, 2012 58Table 22: Product Profile - Provenge 59Table 23: Provenge SWOT Analysis, 2012 63Table 24: Product Profile - Zytiga 65Table 25: Zytiga SWOT Analysis, 2012 67Table 26: Product Profile - Xtandi 69Table 27: Xtandi SWOT Analysis, 2012 71Table 28: Product Profile - Xgeva 73Table 29: Xgeva SWOT Analysis, 2012 75Table 30: Product Profile - Zometa 76Table 31: Zometa SWOT Analysis, 2012 78Table 32: Summary of Other Marketed Hormone and Drug Therapies, 2012 78Table 33: Overall Unmet Needs, Hormone-Sensitive Prostate Cancer - Current Level of Attainment 79
  5. 5. Table 34: Overall Unmet Needs, CRPC - Current Level of Attainment 80Table 35: Clinical Unmet Needs - Gap Analysis, 2012 83Table 36: Prostate Cancer - Phase III Pipeline, 2012 86Table 37: Comparison of Therapeutic Classes in Development for Prostate Cancer, 2012 86Table 38: Product Profile - Cabozantinib 88Table 39: Cabozantinib SWOT Analysis, 2012 92Table 40: Product Profile - Custirsen Sodium 93Table 41: Custirsen Sodium SWOT Analysis, 2012 96Table 42: Product Profile - Sprycel 97Table 43: Sprycel SWOT Analysis, 2012 100Table 44: Product Profile - Yervoy 101Table 45: Yervoy SWOT Analysis, 2012 105Table 46: Product Profile - Orteronel 106Table 47: Orteronel SWOT Analysis, 2012 109Table 48: Product Profile - Alpharadin (radium-223 chloride) 110Table 49: Alpharadin SWOT Analysis, 2012 113Table 50: Product Profile - Tasquinimod 114Table 51: Tasquinimod SWOT Analysis, 2012 117Table 52: Product Profile - ProstVac (Vaccinia-PSA-TRICOM/Fowlpox-PSA-TRICOM) 118Table 53: ProstVac SWOT Analysis, 2012 121Table 54: Sales Forecasts ($m) for Prostate Cancer in the United States, 2012-2022 123Table 55: Key Events Impacting Sales for Prostate Cancer in the US, 2012-2022 125Table 56: Prostate Cancer Market in the US - Drivers and Barriers, 2012-2022 125Table 57: Key Launch Dates 145Table 58: Key Patent Expiries and Market Exclusivity Expiries 146Table 59: Physicians Surveyed, By Country 1591.2 List of FiguresFigure 1: General Treatment Algorithm for Prostate Cancer, 2012 19Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2012-2022 87Figure 3: Sales for Prostate Cancer in the United States by Drug Class, 2012-2022 124For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441Website: http://www.rnrmarketresearch.com/

×